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Abstract
Background: There is rising incidence of gastroenteropancreatic neuroendocrine tumours (GEP- NETs) in many
parts of the world, but epidemiological data from Asian populations is rare.
Methods: We conducted a retrospective study in a tertiary medical centre in Hong Kong, using updated diagnostic
criteria. The presentation, clinical features, and disease outcome were reviewed for all patients with GEP-NETs
confirmed histopathologically at the Prince of Wales Hospital, the Chinese University of Hong Kong, between 1996
and 2013, according to the latest 2010 World Health Organization Classification.
Results: Among 126 patients, GEP- NETs were found in pancreas (34.9 %), rectum (33.3 %), and stomach (8.7 %),
and most of them were non- functional GEP- NETs (91.3 %), mostly of grade 1 (G1) (87.3 %), and about 20 % had
metastases on presentation. Age under 55 years, G1 tumours and absence of metastases were significant favourable
predictors for survival in univariate analysis; whereas G2/3 tumours, size ≥2 cm, and metastases were significant
predictors for disease progression (p < 0.05). In multivariate analysis, age and metastases on presentation were
significant predictors of mortality (respective hazard ratios [HR] 1.05 [95 % confidence interval {CI} 1.02-1.08] and
6.52 [95 % CI 3.22-13.2]) and disease progression (respective HRs 1.05 [95 % CI 1.02-1.07] and 4.12 [95 % CI 1.96-
8.68]), while higher tumour grade also independently predicted disease progression (HR 5.17 [95 % CI 2.05-13.05])
(all p < 0.05).
Conclusion: Non-functional tumours with non-specific symptoms account for the vast majority of GEP-NETs in this
Chinese series. Multidisciplinary approach in the management of patients with GEP-NETs may help improve the
treatment efficacy and outcome.
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Background
Neuroendocrine tumours (NETs) refer to tumours ori-
ginating from neural and endocrine structures distributed
throughout the body. They are tumours of the interface be-
tween the endocrine and the nervous systems [1]. NETs
comprise a heterogeneous family with wide and complex
clinical behaviours [2, 3], and they can develop at any sites,
with the majority from the gastroenteropancreatic system.
Over the years, the nomenclature and classification of
NETs have undergone tremendous changes. In 1907,
Oberndofer first described these tumours arising from
the epithelial cells in small intestine as “carcinoid”, signi-
fying their relatively indolent growth and “cancer-like”
behaviour but not exactly cancers that are more aggressive
[4, 5]. It was not until 2000, the term “neuroendocrine tu-
mours” (NETs) was used officially in the WHO Classifica-
tion, to replace “carcinoid”, which better depicted their
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malignant potential. In 2010, the WHO classification
added a grading system based on the proliferative activity
into either G1 (equivalent to carcinoids), G2 or G3 tu-
mours, the latter two were regarded as neuroendocrine
carcinomas (NECs).
Most NETs occur in the gastrointestinal tract [6]. In
the SEER database (Surveillance Epidemiology and End
Results database of the National Cancer Institute) of the
United States, there was substantial rise in the overall
incidence of gastroenteropancreatic neuroendocrine tu-
mours (GEP- NETs) in the past 30 years, from 1.00 case
per 100,000 in the period of 1973–1977, to 3.65 cases
per 100,000 in the period of 2003–2007. The statistically
significant rise was persistent over the years and was
observed across all GEP-NET embryologic subgroups
and primary sites [5, 7]. In the SEER database and in
many nation-wide cancer registries in other European
countries, the increase in overall incidence of GEP-NETs
was attributed to the increasing use of abdominal im-
aging and endoscopy, as well as the inclusion of both
benign and malignant GEP-NETs in the registries.
Compared with western countries, there were only a
few retrospective studies in Asian countries including
Korea, China, Taiwan, India and Malaysia [8–12]. Most
of the studies in Asia and the western countries have
not used the most updated WHO 2010 Classification,
and only very few of them provided data on the long
term outcomes. This study aims to provide a detailed
analysis of prognosis and outcomes among Chinese pa-
tients with GEP-NETs by describing their clinical char-
acteristics, pathological features and clinical outcomes of
these patients spanning 16 years at a tertiary endocrine
centre in Hong Kong, and to identify the predictors of
clinical outcomes.
Methods
Clinical information for all patients with histologically
confirmed gastroenteropancreatic neuroendocrine tu-
mours (GEP-NETs) from the Prince of Wales Hospital,
Hong Kong, during the period from January 1996 to
August 2013 were identified and included in this ana-
lysis. The histological diagnosis and date were retrieved
from the Laboratory Information System (LIS) main-
tained by the Department of Anatomical and Cellular
Pathology, Prince of Wales Hospital, Hong Kong.
Hand-written and electronic case notes, case summar-
ies and investigation reports of each patient were
reviewed to establish patient’s demographic informa-
tion, details of clinical, biochemical, histopathological
and endoscopic or radiological diagnosis of GEP-NETs,
subsequent treatment modalities and outcomes. The
date of diagnosis was defined as the date of confirmed
histological diagnosis of GEP-NETs. For the diagnostic
endoscopy or imaging modality, it was defined as the
first investigation performed with successful detection
of the tumour. Date of progression referred to the date
of investigation confirming either local or metastastic
progression endoscopically or radiologically. Overall
survival was defined as the time from the date of diag-
nosis to death from all causes in deceased patients, or
to the date of last follow-up otherwise. The duration
for “progression-free” disease was defined as time of
diagnosis to the date of death, or confirmation of re-
gional or distant metastases.
This study was approved by the Joint Chinese Univer-
sity of Hong Kong – New Territories East Cluster Clin-
ical Research Ethics Committee (Reference number:
CREC 2013.031), and is in compliance with the Declar-
ation of Helsinki.
Histological diagnosis, immunohistochemical staining and
grading of tumour
The histological slides of each patient were reviewed by
one pathologist. Immunohistochemical staining, Ki-67,
chromogranin A and synaptophysin staining were per-
formed for all specimens. For pancreatic NETs (pNETs),
functional hormonal staining, including gastrin, somato-
statin, serotonin, glucagon and insulin, was performed in
all specimens. Proliferative indices, Ki-67 and mitotic
rate in each specimen were reassessed again to estimate
the tumour proliferative activities, and to determine the
grade of the tumour according to the WHO 2010 Classi-
fication [13]. Tumours with a Ki-67 index of <2 % were
classified as G1 tumours, index of 3–20 % were classified
as G2, greater than 20 % as G3. Likewise, tumours with
mitotic rates of <2/10 HPF were classified as G1, those
of 2 to 20/10 HPF were classified as G2, greater than 20/
10 HPF as G3. If the grading of Ki-67 index disaccorded
with the mitotic rate, the higher one was preferred.
Statistical analysis
Data is presented as mean ± SD or median (range).
Kaplan-Meier and log-rank test were used for univariate
analysis of factors including gender, age, primary tumour
site (pancreas versus gastro-intestinal-hepatobiliary
tract), tumour size, tumour grade according to WHO
2010 classification, chromogranin A immunostaining
positivity, functional status of tumour (function versus
non- functional tumours), as well as presence of regional
lymph node or distant metastasis on presentation. Cox
proportional hazard model was used for multivariate
analysis of hazard ratio. All statistical tests were two-
sided with p-value <0.05 being considered as statistically
significant. Statistical analysis was performed using the
Statistical Package for Social Science Version 18.0 for
Windows software package.
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Results
Patient characteristics, clinical presentation and
diagnostic trend
We identified a total of 126 patients diagnosed with
GEP-NETs, 64 (50.8 %) of them were male and 62
(49.2 %) were female. The mean age of diagnosis was
56.6 ± 15.2 years old (range 21-98 years old). The most
common primary sites were pancreas (34.9 %, n = 44),
followed by rectum (33.3 %, n = 42), and stomach (8.7 %,
n = 11). Three (2.4 %) patients had confirmed von Hip-
pel- Lindau syndrome, and one patient had multiple
endocrine neoplasia type 1 (MEN1). All of these four
patients with associated familial syndromes had non-
functional pNETs.
The vast majority of GEP-NETs were non- functional
(91.3 %, n = 115). Among the 11 functional tumours,
insulinoma (81.8 %, n = 9) accounted for the majority,
while the remaining two tumours included a gastrinoma
and an ACTH-secreting pancreatic tumour. As for the
non-functioning GEP-NETs, most patients presented
with non-specific gastrointestinal symptoms, including
epigastric or abdominal pain (33.3 %, n = 42), gastro-
intestinal bleeding (18.3 %, n = 23), diarrhoea or change
in bowel habit (5.6 %, n = 7) and painless progressive
jaundice (4.0 %, n = 5). Other manifestations included
symptomatic anaemia (4.0 %, n = 5) and weight loss
(2.4 %, n = 3), and one of them presented with pyrexia of
unknown origin. About 20 % (n = 25) of our patients
presented as incidental finding when they had abdominal
imaging or endoscopies performed for other purposes
such as cancer screening. The remaining four patients
were identified in the regular screening of diseases asso-
ciated with known familial syndromes VHL and MEN1.
The distribution and presenting symptoms of patients
with GEP-NETs from different sites are detailed in
Table 1.
The number of GEP-NETs diagnosed in different time
periods from 1996 to 2013 were presented in Table 2.
This reflected a substantial increase in the number of
pancreatic, rectal and stomach NETs over this time
period, which can probably be attributed to the more
popular use of abdominal imaging and endoscopy over the
past decade. The most common diagnostic procedure was
colonoscopy (31.7 %, n = 40), followed by oesophago-
gastro-duodenoscopy (11.1 %, n = 14). Endoscopic ultra-
sonography (7.9 %, n = 10) was increasingly used. On the
other hand, computed tomography (CT) scan was the
most common initial imaging (19.8 %, n = 25), followed by
ultrasound (11.9 %, n = 15) and magnetic resonance-
imaging (MRI) (2.4 %, n = 3). A significant proportion were
identified as incidental finding during operation for other
clinical indications (13.5 %, n = 17). The clinical diagnostic
information was not available for two of the cases.
Histopathological characteristics
The median size of the tumours was 1.5 cm (range: 0.1–
16.5 cm), of which 87.3 % (n = 110) and 98.4 % (n = 124)
were positive for chromogranin A (CgA) and synapto-
physin respectively. The majority of the tumours were
G1 (87.3 %, n = 110). In addition, 26 patients (20.6 %)
had lymph node or distant metastases on presentation
and six of them had multiple metastases. The most com-
mon sites of metastases were regional lymph nodes and
liver (53.8 % each). The most common tumour associ-
ated with regional or distant metastases were pancreas
(n = 8), followed by rectum (n = 5), stomach (n = 4) and
ileum (n = 4).
Clinical outcome
Treatment modalities
Most patients underwent curative endoscopic or surgical
resections (80.2 %, n = 101) whereas 4.0 % (n = 5)
Table 1 Distribution of primary tumour sites and corresponding presenting symptoms
Primary tumour site Patients, N (%) Male, N Female, N Main clinical symptoms
GI Tract 77 (61.1 %) 43 44
Stomach 11 (8.7 %) 6 5 Abdominal Pain, Gastrointestinal Bleeding, Anaemia
Duodenum 6 (4.8 %) 2 4 Abdominal Pain, Gastrointestinal Bleeding
Ileum 6 (4.8 %) 3 3 Abdominal Pain, Incidental Finding
Appendix 10 (7.9 %) 5 5 Abdominal Pain
Descending Colon 1 (0.8 %) 1 0 Gastrointestinal Bleeding
Sigmoid Colon 1 (0.8 %) 0 1 Abdominal Pain
Rectum 42 (33.3 %) 26 16 Gastrointestinal Bleeding, Incidental Finding
Pancreas 44 (34.9 %) 18 26 Incidental Finding, Abdominal Pain, Hypoglycaemia for Insulinoma
Hepatobiliary System 5 (4.0 %) 3 2
Liver 4 (3.2 %) 2 2 Abdominal Pain
Cholecystoduodenal Fistula 1 (0.8 %) 1 0 Anaemia
Chan et al. BMC Endocrine Disorders  (2016) 16:12 Page 3 of 9
received operations as palliative measures to relieve
tumour-related intestinal or biliary obstructions. Common
non-chemotherapy agents administered as adjunct pre-
operative medical treatment were diazoxide for insulino-
mas (n = 7) and proton-pump inhibitors (n = 1) for gastri-
noma. Chemotherapy was used in eight patients, almost
always for the purpose of palliative care (n = 7). The
chemotherapy usually involved combination regimens with
platinum-etoposide (n = 4), platinum with 5-fluoruracil
(n = 1), platinum-doxorubicin (n = 1), irinotecan cape-
citabine therapy (n = 1) and streptozocin plus 5-fluoruracil
(n = 1). One patient received platinum-etoposide palliative
chemotherapy for recurrent metastatic liver NET and
because of lack of response to transcatheter hepatic arter-
ial chemoemobolization (TACE). Palliative radiotherapy
was used in two patients with bone metastases to sacrum
and right femur. Intra-arterial yttrium-90 microspheres
were used in one patient with pNET with liver metastasis.
Local-regional therapies such as TACE were used in six
patients. Radiofrequency ablation (RFA) was used in one
patient with relapse of liver metastasis. Octreotide was
used in one patient as pre- operative medical treatment
for benign insulinoma. Six patients who presented with
metastatic diseases at the time of diagnosis received pallia-
tive care.
Mortality
One hundred and twenty three patients received long-
term follow up with a median duration of 3.23 years
(range 0.04–17.15 years). Three of the cases were either
lost to follow-up or with their medical case notes unable
to be retrieved. The 1-, 3- and 5-year-survival rates were
83.4, 76.0 and 69.3 % respectively. The majority of mortal-
ity were related to the tumour (57.9 %, n = 22 out of 38).
Local/ metastastic relapses
For the 101 patients who received curative surgical or
endoscopic resection, 8.9 % (n = 9) had local (n = 4) or
metastatic relapse (n = 5), all of which were secondaries
to the liver. One patient had local recurrence of insuli-
noma in the pancreas. The remaining eight patients had
their primary tumour in the pancreas (n = 4, 50 %), rec-
tum (n = 3, 37.5 %) and descending colon (n = 1, 12.5 %).
Prognostic factors for survival and disease progression
Univariate analysis was performed using patients’ age
(55 years old as the cut-off point which corresponds to
the median age in our study), gender, tumour site
(gastrointestinal-biliary tract versus pancreas), tumour
grade according to WHO 2010 classification (Grade 1
tumours versus Grade 2 and Grade 3 tumours), size
(2 cm as cut-off point), chromogranin A immunostatin-
ing positivity, functional status, and presence of metasta-
sis on presentation, to identify potential prognostic
factors for survival and disease progression. Age younger
than 55 years old (p = 0.006), G1 tumours (p = 0.001),
and absence of metastasis on presentation (p < 0.001)
were significant predictors of better survival by univari-
ate analysis.
For disease progression, tumours grading higher than
G1 (p < 0.001), tumours larger than or equal to 2 cm
(p = 0.031), and presence of metastasis on presenta-
tion (p < 0.001) were significant predictors of disease
progression (Table 3). Survival curves and disease pro-
gression-free period curves using Kaplan-Meier estimates
are displayed in Figs. 1 and 2, respectively. Multivariate
analysis using the Cox regression hazard model confirmed
that both age and presence of metastasis on presentation
were significant independent predictors of mortality and
disease progression. Tumour grade was also identified as a
significant independent predictor for disease progression
(Table 4).
Discussion
In this large retrospective analysis of GEP-NETs in Chin-
ese classified according to the latest WHO 2010 Classifica-
tion, non-functional tumours with non-specific symptoms
accounted for the vast majority disease presentation. We
Table 2 Distribution of GEP- NETs by site across the different periods
Site 1996–2001 2002–2007 2008–2013 Total
Pancreas 11 19 14 44
Rectum 8 17 17 42
Stomach 1 5 5 11
Appendix 3 5 2 10
Ileum 1 4 1 6
Duodenum 0 3 3 6
HBP 2 0 3 5
Colon 0 1 0 1
Sigmoid 0 0 1 1
Total number diagnosed during period 26 54 46 126
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Table 3 Overall survival and progression- free disease period
Factors Overall Survival Progression- Free Disease Period
Number Mean (Yrs) 95% CI x2 p Number Mean (Yrs) 95% CI x2 p
All Patients 123 10.84 9.25–12.42 123 9.91 8.34-11.48
Gender 0.122 0.727 0.919 0.338
Male 62 8.04 6.71–9.38 62 7.19 5.84–8.53
Female 61 11.12 8.90–13.34 61 10.69 8.44–12.94
Age 7.493 0.006 2.775 0.096
<55 56 13.56 11.68–15.44 56 11.55 9.42–13.69
≥55 66 7.06 5.47–8.64 66 7.06 5.47–8.64
Site 2.887 0.089 1.202 0.273
GIH 80 7.94 6.58–9.29 80 7.59 6.24–8.94
Pancreas 43 12.53 10.14–14.93 43 10.88 8.42-13.35
Tumour Grading
G1 106 11.57 9.93–13.22 11.869 0.001 106 10.69 9.04–12.34 15.232 <0.001
G2 or G3 14 3.28 1.37–5.18 14 2.86 1.26–4.45
Size 2.632 0.105 4.660 0.031
<2cm 67 12.31 10.11–14.51 67 11.82 9.63–14.01
≥2cm 44 8.61 6.75–10.48 44 7.51 5.68–9.34
Chromogranin A Staining 0.119 0.730 0.347 0.556
Positive 107 10.86 9.16–12.55 107 10.03 8.35–11.70
Negative 16 7.81 4.46–11.17 16 6.93 3.71–10.14
Functionality 2.915 0.088 2.315 0.128
Non- functional 113 8.69 7.48–9.90 113 8.04 6.83–9.24
Functional 10 15.36 12.24–18.49 10 13.92 10.11–17.73
Metastases on Presentation 44.760 <0.001 41.259 <0.001
Yes 26 3.39 1.83–4.94 26 3.18 1.74–4.61
No 96 12.29 11.60–14.98 96 12.23 10.47–13.98
Fig. 1 Overall survival. a By age - green line indicates age≥ 55 years old and blue line indicates age < 55 years old (p = 0.006). b By tumour grade
(WHO classification) - green line indicates WHO grade 2 or grade 3 tumours and blue line indicates grade 1 tumours (p = 0.001). c By metastasis
on presentation - green line indicates metastasis on presentation and blue line indicates no metastasis on presentation (p < 0.001)
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also noted significant heterogeneity in the overall prognosis
and outcome.
In older Western literature, the small intestine and the
appendix were the most common sites of GEP-NETs
[5, 14, 15]. Over the past two decades, with increas-
ing availability of endoscopic imaging, rectal NETs
have become more common. Among registries in Asia,
rectum, pancreas and stomach were the most common
primary sites [8–12]. Similarly, rectum (33.3 %) and pan-
creas (34.9 %) were the most frequently reported sites of
GEP-NETs in this analysis, with stomach and appendix
together accounting for less than 10 % each. The discrep-
ancy between Western and Asian reports may be due to
racial disparities and study design. It should be noted that
most of the Western data were derived from population-
based studies [5, 14–19], while data in Asia countries were
often based on experiences in a single centre or “multiple-
centred” studies from limited number of hospitals [8–12].
Nevertheless, this apparent difference in the distribution
of GEP-NETs between Asian series and studies reported
from the US or Europe may warrant further investigation.
In some series, the Williams and Sandler classification
was used [20]. This classification categorizes NETs ac-
cording to their derivative origins into foregut (lung,
stomach, duodenum, proximal jejunum and pancreas),
midgut (distal jejunum, ileum, appendix and caecum),
and hindgut (transverse and left- sided colon and rec-
tum) [20, 21]. A nationwide epidemiological survey from
Japan revealed that hindgut tumours, instead of midgut
tumours, were the most common among all GEP- NETs
in the Japanese population, with the midgut tumours be-
ing the least common [22]. This is in contrast to the
Western population [23]. In our study, however, foregut
tumours from the pancreas and the stomach accounted
for more than one- thirds of all GEP- NETs when the
Williams and Sandler classification was adopted. It was
thought that this classification by site of origins fails to
provide useful pathological and clinical information to
prognosticate patients with NETs. It is also imprecise to
distinguish different biologically relevant GEP- NETs en-
tities. For example, the foregut tumours which can be
from pulmonary, gastric and duodenal, or pancreatic in
origin, are too different in their morphology, function
and biology to be classified in a single group [24].
Over 90 % of GEP-NETs in our study were non-
functional tumours. Of the functional tumours, 82 %
were pNETs. The age of diagnosis of functional pNETs
was almost 10 years younger than that of non-functional
ones, with insulinomas being the most frequently encoun-
tered functional tumour. The younger age of presentation
is due to the presence of specific symptoms by functional
tumours such as recurrent unprovoked hypoglycaemic at-
tacks in patients with insulinomas. While the majority of
Fig. 2 Overall disease progression. a By tumour grade (WHO classification) - green line indicates WHO grade 2 or grade 3 tumours and blue line
indicates grade 1 tumours (p < 0.001). b By tumour size - green line indicates tumours≥ 2 cm and blue line indicates tumours <2 cm (p = 0.031).
c By metastasis on presentation - green line indicates metastasis on presentation and blue line indicates no metastasis on presentation (p < 0.001)
Table 4 Cox multivariate analysis for overall survival and disease
progression
Mortality
Variables HR 95 % CI p
Age 1.05 1.02–1.08 <0.001
Presence of Metastases on Presentation 6.52 3.22–13.19 <0.001
Disease Progression
Age 1.05 1.02–1.07 0.001
Presence of Metastases on Presentation 4.12 1.96–8.68 <0.001
Tumour Grade 5.17 2.05–13.05 0.001
Variables included in the regression model: age (as continuous variable),
tumour size (<2 cm versus ≥2 cm), tumour grade (Grade 1 versus Grade 2 and
Grade 3) and status of metastases on presentation (presence of metastases
versus no metastasis on presentation). Only significant variables are shown in
the table
HR hazard ratio, CI confidence interval
Chan et al. BMC Endocrine Disorders  (2016) 16:12 Page 6 of 9
functional NETs resided in the pancreas, non- functional
pNETs nevertheless accounted for the greater proportion.
The widespread use of abdominal imaging during work-
up for non-specific symptoms may have contributed to
the detection of pNETs at an early stage before the devel-
opment of functional manifestation. Of note, none of our
patients presented with carcinoid syndrome, in contrast to
the Western populations [12]. Two other single-centred
studies in China and Korea also reported low rates of car-
cinoid syndrome [11, 12]. The reason for this ethnic dis-
parity in the occurrence of carcinoid syndrome is not
known.
In this study, regional lymph node and distant metas-
tases occurred in 20.6 %, which is lower compared with
the rates (23.0 to 53.4 %) reported by other studies [12,
23]. Most of the GEP- NETs in our review were G1 well-
differentiated tumours found incidentally. The lower fre-
quency of small intestine NETs which have greater pro-
pensity to metastasize may also account for the relatively
lower rate of metastases in our data [12].
In terms of prognostic factors, smaller tumour size,
lower tumour grade and absence of metastasis were as-
sociated with better survival and less likelihood of dis-
ease progression in our study, which concurred with a
large retrospective cohort study in Germany [25]. In
contrast to results from a single-centre study in Guang-
dong, China, which demonstrated positive correlation of
positive functional status of GEP-NETs with survival in
univariate analysis [12], functional status was not found
to associate with either disease progression or survival in
our analysis. Such discrepancy could be explained by the
much smaller number of insulinoma, as well as the over-
all small proportion of functional tumours in our series.
Endoscopy, USG, CT and MRI remain the most popu-
lar diagnostic modalities of GEP-NETs in the current
study. In general, the sensitivity of CT and MRI to detect
GEP-NETs was estimated to be 28.6 to 94.4 %, and 84 to
95 %, respectively [26]. CT may pick up insulinomas lar-
ger than 1 cm in size but not the smaller ones. In this
study, biphasic thin section helical CT was performed in
all seven patients with insulinoma in whom imaging his-
tory was available. Three of them had negative CT find-
ings and the pancreatic tumours were subsequently
detected by EUS with the size of insulinomas ranging
from 1.2 to 2 cm. The vast majority of NETs are slow-
growing with low proliferative index, and express somato-
statin receptors, especially subtype 2 (SSTR2) [26, 27].
This forms the basis of somatostatin receptor imaging
(SRI) and the rationale for treatments including somato-
statin analogue and peptide-receptor radionuclide therapy
(PRRT) [27]. 111In-DTPA-octreotide is currently the most
commonly used radioactive-ligand for somatostatin recep-
tor scintigraphy [27, 28]. The detection rate of 111In-
DTPA-octreotide scintigraphy is better for gastrointestinal
NETs with sensitivity ranging from 80 to 100 % [28], but
lower for insulinomas with sensitivity 20 to 60 % [26], as
not all insulinomas express SSTR2 [29]. The only three
patients with insulinoma in this study who had 111In-
DTPA scan performed all had negative findings, and the
pancreatic lesions were detected using CT or MRI. There
are no known uniform guidelines regarding imagings for
GEP- NETs. In general, no single technique is 100 % sensi-
tive and specific, multiple imaging modalities should be
considered individually to detect small GEP-NETs [26].
Immunohistochemical staining for synaptophysin
(Syn) and chromogranin A (CgA) is regarded as part of
the standardized pathological assessment of GEP-NETs
[30]. Being part of the membrane of neurosecretory hor-
mone granules, positive staining of CgA is strongly
dependent on the number of neurosecretory vesicles per
cell [13]. CgA is more frequently elevated in well-
differentiated tumours compared to poorly differentiated
tumours. In our study, CgA was positively stained in im-
munohistochemical staining in 87.3 % (n = 110) of pa-
tients. In the remaining 16 CgA-negative patients,
however, only two were poorly- differentiated neuroen-
docrine carcinomas. Synaptophysin (Syn) is a peptide of
the small synaptic vesicles present in all neuroendocrine
cells [31]. It can be demonstrated in all NETs. In our
study, synaptophysin staining was positive in up to
98.4 % (n = 124 out of 126), consistent with the high sen-
sitivity of Syn in diagnosis of NETs. Interestingly, immu-
nohistochemical staining for insulin was positive in only
six of the nine patients with insulinoma in this study.
The negative immunoreactivity for insulin may indicate
the production of precursor, or pro-insulin by tumour
rather than insulin itself. Moreover, insulin molecules
themselves or the antigenicity of insulin molecules may
be lost during tissue processing and subsequent immu-
nohistochemical staining.
Among the many therapeutic options for GEP-NETs,
surgical treatments of both curative and debulking pur-
poses are the mainstay treatment of choice. Most pa-
tients in this review underwent curative endoscopic or
surgical resections. In patients with liver metastasis,
treatment streams include surgery, loco-regional ther-
apy, systemic medical therapy and ablative procedures
such as radiofrequency ablation (RFA), and trans-arterial
embolization (TAE) or chemoembolization (TACE). The
six patients in our study who received RFA (n = 1) or
TACE (n = 5) experienced recurrence of new metastatic
liver lesions after RFA or TACE over a duration of 6 to
14 months. There have not been any randomized trials
to examine the superiority of one ablative therapy over
another [3].
In terms of systemic medical treatment, there has been
adjuvant or neo-adjuvant therapies recommended for high
grade NETs after surgery. Traditional chemotherapy is
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recommended for pNETs, metastatic foregut G2 NETs,
and in any G3 tumours with or without liver metastases
from various primary sites in the GI tract [32]. In general,
well-differentiated NETs are resistant to most chemother-
apeutic agents because of their slow proliferation. In our
study, patients having metastatic NETs from the gut trad-
itional chemotherapy such as platinum-based agents, all
had static or progressive disease after several cycles of
chemotherapy. For somatostatin analogues (SA) such as
octreotide and lanreotide, they have their therapeutic
values proven in functional NETs and metastatic G1 NETs
in the midgut. The reported ability for SA to achieve dis-
ease stabilization is up to 50–60 % in patients with ad-
vanced or metastatic well-differentiated NETs [32, 33].
Another trial also confirmed the anti- proliferative ac-
tivity of lanreotide for well-to- moderately differenti-
ated non-functional GEP-NETs [33]. In this study,
none of the patients received SA. Sunitinib and everolimus
are both approved targeted therapies for well- differenti-
ated pNETs. Only one patient of our study used sunitinib.
He had von-Hippel Lindau disease and recurrent inoper-
able non-functional pNET. His pancreatic NET remained
unchanged in size for almost three years since the com-
mencement of sunitinib. In our locality, cost is the major
constraint of using targeted therapy in metastatic pNETs.
There is at present no evidence to support the efficacy of
sunitinib and everolimus in treating extra- pancreatic
NETs.
To the best of our knowledge, this retrospective review
on GEP-NETs at a local tertiary centre is one of the first
to report on the clinical presentation, pathological charac-
teristics, investigation and treatment modalities, as well as
prognostic factors of GEP-NETs in Asia. In our study, the
immunohistochemical staining of chromogranin A and
synaptophysin, together with the proliferative indices of
Ki-67 and mitotic rate, were re-assessed by one patholo-
gist to ensure the completeness and uniformity of the im-
portant pathological information of all specimens. In this
way, the grading of the tumour according to the WHO
Grade Classification 2010 was assessed accurately to facili-
tate the analysis of the prognostic significance of tumour
grade on survival and disease progression. This approach
was not possible in the previously published nation-wide
registries in western countries, and was not yet adopted in
the most single or multi-centre retrospective studies in
Asian countries either [8–11].
There are a number of limitations in this single-
centred study, with the major one being the comparatively
small number of patients, as well as a small number of
events especially mortality. Overall survival was adopted
as endpoint rather than disease- specific survival because
of this. The retrospective nature of the study also revealed
the heterogeneity of disease management among different
clinicians in the same tertiary centre under the lack of
consensus and guidelines of the management of GEP-
NETs. Individual preferences in choosing radiological or
biochemical tests for disease staging in diagnosis and dis-
ease surveillance were potentially significant factors that
could affect the analyses of possible prognostic factors
contributing to disease- free survival and mortality. Be-
sides, we could only evaluate the actual number of pancre-
atic, rectal and stomach NETs diagnosed over different
time periods from 1996 to 2013 (Table 2) as it was difficult
to calculate the overall incidence rate of GEP-NETs which
are still overall a rare disease entity. Moreover, only GEP-
NETs with confirmed histological diagnosis were included
but not those with only radiological diagnosis. This might
exclude patients with advanced disease and large tumour
sizes, or patients with multiple metastases which was not
resectable for histological diagnosis. Hence, a small num-
ber of patients with particularly poor prognosis might
have been excluded from the study, leading to the reduced
event rate related to the tumour. Taking this into consid-
eration, age may be more of a predictor of overall survival
rather than disease- specific survival. Given the study limi-
tations, multidisciplinary approach for patients with GEP-
NETs, which involves coordinated delivery of care by a
team of specialists from related specialties [34], is ex-
pected to be the trend for treatment in the foreseeable fu-
ture. Multidisciplinary practice allows a more uniform yet
individualized management plan for each patient based on
updated treatment guidelines and trend. From an aca-
demic and research point of view, multidisciplinary care
also facilitates large- scale epidemiological research to
study the disease pattern, and other opportunities for clin-
ical trials of new treatment options in the future.
Conclusions
This single-centred retrospective review in Hong Kong
provides an expedient description of the epidemiology,
clinic-pathological features, management and prognostic
factors of GEP-NETs in Asians. With the emergence of
various diagnostic and treatment modalities, multidiscip-
linary care is of paramount importance to improve effi-
cacy of treatment, and the clinical outcomes of patients
with GEP- NETs. Further understanding of the molecu-
lar mechanisms may improve the treatment and progno-
sis of patients with GEP-NETs.
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